GRAIL, Inc.

On the latest episode of The Cancer SIGNAL podcast, host Susanna Quinn is joined by Nima Nabavizadeh, MD, from Oregon Health & Science University, to discuss the groundbreaking PATHFINDER 2 study findings. Listen here: https://bit.ly/48DGcwp

#EarlyCancerDetection #MCED

Today we announced that we have entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents’ fees and other expenses. Learn more: grail.com/press-releas...

70% of cancer deaths are from cancers that do not have recommended screening tests. In the PATHFINDER 2 study, presented at #ESMO25, approximately three-quarters of the cancers detected by Galleri do not have standard of care screening options. Learn more: https://bit.ly/4n91cP6

Press following #ESMO25:
Join the Press Briefing II - today, 12:30-13:15 CEST, as Dr. Nima Nabavizadeh discusses “Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study.”

Coming up tomorrow at #ESMO25 in Berlin - results from the PATHFINDER 2 study. See our press release for more details: https://bit.ly/4n91cP6

It’s #MensBreastCancerAwareness Week, an ideal time to remind everyone that, while rare, #MenGetBreastCancerToo—and they should see their doctor immediately if they notice any unusual symptoms.

#EarlyDetection can help improve their chances for successful treatment.

#LiverCancer is the fourth most common cause of cancer death worldwide, and hepatocellular carcinoma (HCC), which accounts for nearly 75% of all cases, is often diagnosed in advanced stages. We’re observing #LiverCancerAwarenessMonth by promoting #EarlyDetection.

#OctoberIs4Livers

After 20 years of serving her local police department, Darla took a multi-cancer early detection (MCED) test through her insurance company. Despite having no symptoms, her test detected a cancer signal, giving her the chance to take swift action and become cancer free today. https://bit.ly/47aCE3o

How do we bring multi-cancer early detection (MCED) into everyday clinical practice? With more than 35,000 participants, PATHFINDER 2 is the largest U.S. interventional MCED study to date. Ahead of #ESMO25, our president, Dr. Josh Ofman, shares what these data mean: https://bit.ly/46EECck

For #BreastCancerAwarenessMonth, we’re calling out the importance of #EarlyDetection—especially if you’re at risk for the BRCA gene mutation. Learn more by listening to The Cancer SIGNAL: https://bit.ly/4pTkTxc

Celebrate #InternationalPodcastDay by giving The Cancer SIGNAL a listen. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)—from patients to doctors, advocates to researchers, and more. Tune in today: https://bit.ly/47oQpMD

#PodcastCommunity #EarlyCancerDetection

#GynecologicCancerAwarenessMonth serves as a reminder of the importance of routine screenings for detecting cervical cancer early and improving prognosis and treatment success.

#GCAM #PreventCervicalCancer

Tad Carper, a @dallas--cowboys.bsky.social exec, took a multi-cancer early detection (MCED) test—which led to an unexpected journey. Hear how early detection shaped his story on the latest episode of The Cancer SIGNAL podcast:

Apple Podcasts: https://apple.co/4mI2WPm

We’re presenting new data from our PATHFINDER 2 study at the European Society for Medical Oncology 2025 Congress. We are also pleased to be sharing results from our SYMPLIFY and REFLECTION studies at the 2025 Early Detection of Cancer Conference. Read more: https://bit.ly/4nc39Lu #ESMO25

You can observe #WorldLymphomaAwarenessDay by putting your health first and paying attention to unusual symptoms—especially if you’re at high risk for lymphoma—as well as getting regular checkups. Remember that early detection can help ensure more treatment options.

#WLAD

A few compelling numbers in time for Ovarian Cancer Awareness Month: Stage I can be cured in up to 90% of cases, and stage II has a 5-year survival rate of 70%. Yet only 20% are diagnosed at stage I or II, underscoring the need to raise awareness of early detection.

#OvarianCancer #OCAM

Were you aware that while the overall cancer death rate decreased by 34% from 1991 to 2022, the leukemia rate has increased? In observance of Blood Cancer Awareness Month, we’re highlighting the importance of early detection.

#BloodCancerAwareness #Leukemia

Today GRAIL reported second quarter 2025 financial results.

Learn more: grail.com/press-releas...

July is Sarcoma Awareness Month—a time to raise awareness about rare cancers and the importance of early detection. Cancer screenings and a knowledge of symptoms can lead to earlier diagnoses and better treatment outcomes. #SarcomaAwareness #EarlyCancerDetection

Today we announced positive top-line performance and safety results from our registrational PATHFINDER 2 study.

Learn more: grail.com/press-releas...

YouTube video by GRAIL Patient Testimonial: Kevin, Cancer Signal Detected

Lieutenant McFarland, a healthy firefighter, took an #MCED test, leading to a stage 1 #EsophagealCancer diagnosis after diagnostic evaluation. Early detection allowed for a minimally invasive procedure to remove the tumor, helping him avoid chemo and radiation. youtu.be/S7pBNtnxl4w

Today GRAIL reported first quarter 2025 financial results. Learn more: grail.com/press-releas...

Today we announced a new partnership with athenahealth, which will offer healthcare providers streamlined ordering of the Galleri multi-cancer early detection (MCED) test.

Learn more: grail.com/press-releas...

GRAIL is the 2025 Best Overall MedTech Company! We are so proud of this recognition from the 9th annual MedTech Breakthrough Awards program, which is designed to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories.

Only ~20% of ovarian cancers are found at an early stage. And there are no recommended screening tests for people who aren’t at high risk and who do not have symptoms.

This #WorldOvarianCancerDay, hear The Cancer SIGNAL host Susanna Quinn’s experience with ovarian cancer: bit.ly/3RVVzqr

There are currently no standard #BladderCancer screening tests for people at average risk. This #BladderCancerAwarenessMonth, learn more about the potential of multi-cancer early detection (MCED) testing in screening for cancer:

Rx only. See Important Safety Information:
grail.com/multi-cancer...

We’re excited to attend the @theaacr.bsky.social Annual Meeting (AACR) to present new data findings that highlight real-world evidence with the Galleri multi-cancer early detection (MCED) test. See when and where you can find our data presentations: grail.com/press-releas...
#AACR25

This Medical Laboratory Professionals Week, we are recognizing the important work our clinical laboratory personnel and professionals do in the fight against cancer. Thank you for your invaluable contribution to our mission.

#MLPW #lab4life #labweek

Today we welcomed several cancer advocacy organizations to our NC site to tour our state-of-the-art lab and meet with GRAIL senior leaders. It was an incredible opportunity to share our innovative work and explore what is needed to support those impacted by cancer.

Today GRAIL reported fourth quarter and full year 2024 financial results. Read more: grail.com/press-releas...